On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery ...

Celltrion advances its subcutaneous biosimilar portfolio with a new Herzuma trial, following the success of Remsima SC and recent European approvals. Herceptin has been a cornerstone breast cancer ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Purpose The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV ...

Hospitals displayed different uptake patterns of both subcutaneous trastuzumab following the introduction in 2014 and biosimilars in 2018. One hospital kept administering subcutaneous trastuzumab for ...

Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent ...

Patients with unresectable locally advanced or metastatic HER2+ breast cancer were randomly assigned to receive trastuzumab duocarmazine or a physician’s choice.

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

We've already seen applications for approval of a subcutaneous form of atezolizumab [Tecentriq], and we've already seen other subcutaneous formulations of drugs like Rituxan [rituximab] and drugs ...